

**FINAL LIST OF NON-PROPRIETARY; NON-QUALIFIED ONCOLOGY  
PRODUCTS SELECTED AS SPECIAL CASE  
Second Time Tender; November 2016 For PACT (FY: 2016-17)**

<b>S.NO</b>	<b>Description of Product</b>	<b>Company Name</b>	<b>Technical Score</b>	<b>Financial Score</b>	<b>Total</b>	<b>REMARKS</b>
1	Inj. Cisplatin 10 mg	AJM	45	29.79	74.79	<b>Selected</b>
2	Inj. Bleomycin 15 mg	AJM	43	30	73	<b>Selected</b>
3	Inj. Mitomycin 10 mg	AlHabib	43	30	73	<b>Selected</b>
4	Inj. Mitomycin 2 mg	AlHabib	43	30	73	<b>Selected</b>
5	Inj. Dactinomycin 500 mcg	AlHabib	43	30	73	<b>Selected</b>
6	Inj. Daunorubicin 20 mg	AlHabib	41	30	71	<b>Selected</b>
7	Inj. Dacarbazine 200 mg	AlHabib	41	30	71	<b>Selected</b>
8	Inj. Ifosphamide 1000 mg	AlHabib	43	30	73	<b>Selected</b>
9	Inj. 5 FU 250 mg	AlHabib	40	30	70	<b>Selected</b>
10	Inj. 5 FU 500 mg	AlHabib	40	30	70	<b>Selected</b>
11	Inj. Ifosphamide 2000 mg	AlHabib	43	30	73	<b>Selected</b>
12	Inj. Mesna 400 mg	AlHabib	43	30	73	<b>Selected</b>
13	Inj. VCR 1 mg	AlHabib	38	30	68	<b>Selected</b>
14	Inj. VCR 2 mg	AlHabib	38	30	68	<b>Selected</b>
15	Inj. Vinblastine 10 mg	AJM	45	30	75	<b>Selected</b>
16	Inj. Methotrexate 50 mg	AlHabib	43	30	73	<b>Selected</b>
17	Inj. Methotrexate 500 mg	AlHabib	43	30	73	<b>Selected</b>
18	Inj. Methotrexate 1000 mg	AlHabib	41	30	71	<b>Selected</b>
19	Tab Methotrexate 50 mg	AlHabib	43	30	73	<b>Selected</b>
20	Tab Mercaptopurine 50 mg	AlHabib	43	30	73	<b>Selected</b>
21	Inj. Bortezomib 3.5 mg	Revive - UR	48	30	78	<b>Selected</b>
22	Tab. Lenalidomide 10 mg	Revive - UR	48	30	78	<b>Selected</b>
23	Inj. Liposomal Amphotericin B	Revive - UR	48	30	78	<b>Selected</b>
24	Inj. Bendamustine 100 mg	Revive - UR	48	30	78	<b>Selected</b>
25	Inj. Ganciclovir 250 mg	Graton	41	30	71	<b>Selected</b>
26	Inj. Liposomal Doxorubicin 20 mg	Amgomed	42	30	72	<b>Selected</b>

1. All the above products have been selected conditionally as a special case since there were no alternative qualified medicines quoted.
2. UR: Un-registered products selected as a special case subject to terms and conditions.
3. All the Companies/Firms whose products have been selected above should immediately contact Oncology Pharmacist, HMC, Peshawar to sign the contract agreement and deposit Bank/Performance guarantee for issuing of purchase order.

**Prof. Abid Jameel,**

Focal Person & Chairman Purchase Committee,

Treatment of Poor Cancer Patients,

Government of Khyber Pakhtunkhwa, Hayatabad Medical Complex, Peshawar